This study is a multi-center, non-interventional study. Clinicopathologic, treatment , outcome and efficacy data will be collected from medical records in metastatic esophageal squamous cell carcinoma (ESCC) patients.
This study is a multi-center, non-interventional study. Patients' background, treatment pattern, treatment outcome, efficacy will be collected in metastatic esophageal squamous cell carcinoma (ESCC) patients who were treated with chemotherapy combined with immunotherapy as 1st line treatment at approximately 5 institutions. The patients should have received at least 1 cycle of immunotherapy and chemotherapy with or without radiotherapy. Based on these data, overall survival (OS), progression free survival (PFS) from start of 1st line treatment and the role and efficacy of radiotherapy for these patients will be assessed.
Study Type
OBSERVATIONAL
Enrollment
728
chemotherapy:paclitaxel+platinum-based anticancer drugs immunotherapy:anti-PD-1 Immune checkpoint inhibitors
Intensity-modulated radiation therapy
Henan Cancer Hospital
Zhengzhou, Henan, China
Hunan Cancer Hospital
Changsha, Hunan, China
Shanxi Cancer Hospital
Taiyuan, Shanxi, China
Sichuan Cancer Hospital
Chengdu, Sichuan, China
Tianjin Cancer Hospital
PFS
progression-free survival
Time frame: up to 2 years
OS
overall Survival
Time frame: up to 2 years
DoR
Duration of ResponseR
Time frame: up to 2 years
ORR
Objective Response Rate
Time frame: up to 2 years
RP
recurrence recurrence pattern
Time frame: up to 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Tianjin, Tianjin Municipality, China